ClinicalTrials.gg
RecruitingNCT06513949Updated Jul 29, 2026

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

A Phase 2 interventional study of Atibuclimab and Placebo in Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome and Acute Lung Injury, sponsored by Implicit Bioscience. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Implicit Bioscience · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.

Planned enrollment
119th of 250
56 · median 52
Started
2026
with 14 others
Phase 2
74 of 324
8 open now
Primary completion
2029-03
later than 45 of 55 live
Registered
295th of 324
by date

Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 119th largest by planned enrollment of the 250 interventional ones that give a count, is one of 15 that started in 2026, is one of 74 in phase 2, reaches primary completion later than 45 of the 55 other live ones, and was the 295th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 324 studies in Respiratory Distress Syndrome with a site in United States, or all of them as a file.
02

Study summary

Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days.

The primary outcome is the day 4 oxygenation index assessed as a continuous measure.

Read the detailed description

This is a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of anti-CD14 treatment with a recombinant chimeric monoclonal antibody (IC14) in hospitalized patients with Acute Respiratory Distress Syndrome (ARDS). CD14 is a key mediator in recognition of molecular markers of tissue damage (damage-associated molecular patterns, DAMPs) and infection (pathogen-associated molecular patterns, PAMPS).

The primary objective of the study is to determine the efficacy of IC14 in patients hospitalized with ARDS for reducing the severity of lung injury as measured by the day 4 Oxygenation Index (OI) assessed as a continuous measure (mean airway pressure x fraction of inspired oxygen [FiO2] x 100/partial pressure of oxygen [PaO2]). OI captures severity of hypoxemia and concurrent intensity of ventilatory support.

Secondary objectives include determining whether IC14 reduces the systemic and alveolar inflammatory response, and improves indices of oxygenation and illness severity. Exploratory endpoints include determining the effect of CD14 blockade on duration of mechanical ventilation and mortality in patients hospitalized with ARDS. Pharmacokinetic [PK]/Pharmacodynamic [PD] endpoints include determining day 4 IC14 levels in bronchoalveolar fluid (BALF) vs. serum, and determining the feasibility of measuring blood presepsin levels, a CD14-pathway specific biomarker for rapid assessment.

03

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Adult Respiratory Distress Syndrome
  • Acute Lung Injury
  • Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Keywords

  • ARDS
  • IC14
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be included in the study only if they meet all the following criteria:

  1. Adult patients (18+) on mechanical ventilations with acute respiratory distress syndrome (ARDS) by Berlin Criteria (≤48 hours)

    1. P:F ratio \< 300
    2. Positive end-expiratory pressure (PEEP) ≥5 cm H2O
    3. Bilateral opacities on chest x-ray or chest computerized tomography (CT)-- not fully explained by effusions, lobar/lung collapse, or nodules
    4. Respiratory failure not fully explained by cardiac failure or fluid overload
    5. Within 1 week of known clinical insult or new or worsening respiratory symptoms

    i. Common Risk Factors for ARDS: Pneumonia, aspiration, inhalation injury, pulmonary contusion, pulmonary vasculitis, drowning, non-pulmonary sepsis, major trauma, pancreatitis, severe burns, non-cardiogenic shock, drug overdose, multiple transfusions

  2. Patient or Legal authorized representative able to understand and give written

Exclusion criteria

Exclusion Criteria:

An individual fulfilling any of the following criteria should be excluded from enrollment in the study:

  1. Significant pre-existing organ dysfunction prior to hospitalization

    1. Lung: Currently receiving home oxygen therapy as documented in medical record
    2. Heart: Pre-existing congestive heart failure defined as an \<20% as documented in the medical record
    3. Renal: End-stage renal disease requiring renal replacement therapy or estimated (eGFR) \<30 mL/min.
    4. Liver: Severe chronic liver disease defined as Class C or hepatic transaminases >5 times
    5. Hematologic: Baseline count \<50,000/mm3
  2. Presence of co-existing infection, including, but not limited to:

    1. infection not virally suppressed and with pre-hospitalization ≤ 500 cell/mm3
    2. Active tuberculosis or a history of inadequately treated tuberculosis
    3. Active or viral infection
  3. Current treatment, or treatment within 30 days or five half-lives (whichever is longer) with etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®), certolizumab (Cimzia®), golimumab (Simponi®), anakinra (Kineret®), rilonacept (Arcalyst®), tocilizumab (Actemra®), sarilumab (Kevzara®), siltuximab (Sylvant®), or other potent or immunomodulatory drugs or treatments
  4. Receiving comfort measures only
  5. Requiring >2 vasopressors
  6. Pregnant
  7. Prisoners
  8. History of or idiosyncratic reaction to IC14
  9. Women who are currently breastfeeding
  10. Bronchoscopy safety exclusions

    1. P:F \<100 on 100% FiO2
    2. Mean pulmonary artery pressure > 55 mmHg
    3. Marked cardiovascular instability (Mean arterial pressure \<55 mmHg with vasopressor support)
    4. Intracranial pressure ≥20 mmHg
    5. Acute ischemic heart disease (unstable angina or ST-elevation myocardial infarction or Type 1 non-ST-elevation myocardial infarction)
    6. Supported on extracorporeal membrane oxygenation
    7. Endotracheal tube \<6.5 mm
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    IC14 (atibuclimab)

    IC14 (atibuclimab) is a recombinant monoclonal antibody against human CD14

    Biological: Atibuclimab

  • Placebo comparator
    Identical-appearing placebo

    Sterile normal saline

    Other: Placebo

Interventions

  • BiologicalAtibuclimab

    monoclonal antibody against human CD14

    Also known as: IC14

  • OtherPlacebo

    Sterile normal saline for injection

06

What researchers measure

Primary outcomes

  1. Day 4 Oxygenation Index

    (mean airway pressure x fraction of inspired oxygen \[FiO2\] x100)/ partial pressure of oxygen \[PaO2\]

    Time frame: Day 1 through Day 4

Secondary outcomes

  1. Biomarkers of injury and inflammation measured in bronchoalveolar lavage fluid

    Interleukin(IL)-6

    Time frame: Day 4

  2. Biomarkers of injury and inflammation measured in plasma

    Interleukin(IL)-6

    Time frame: Day 4

  3. Oxygenation index

    (mean airway pressure x FiO2 x100)/PaO2

    Time frame: Days 7 and 14

  4. Oxygen saturation index

    (mean airway pressure x FiO2 x100)/peripheral oxygen saturation \[SpO2\]

    Time frame: Days 4, 7, and 14

  5. P:F ratio

    Ratio of partial pressure of arterial oxygen (P) to fraction of inspired oxygen (F)

    Time frame: Days 4, 7, and 14

  6. S:F ratio

    Ratio of the arterial oxygen saturation (S) to fraction of inspired oxygen (F)

    Time frame: Days 4, 7, and 14

  7. Sequential Organ Failure Assessment (SOFA) Score (range 0 [best] to 24 [worst])

    Disease severity scale

    Time frame: Days 4, 7, and 14

  8. Time to blood presepsin level

    Time from study consent to measurement completion of blood presepsin level via the PATHFASTTM instrument

    Time frame: Days 0-4

  9. Cumulative incidence of run failures

    Defined as not completing presepsin measurement between consent and infusion of study drug

    Time frame: Days 0-1

  10. Cumulative incidence of protocol-specified exempt serious events

    protocol-specified exempt serious events

    Time frame: Days 1-28

  11. Cumulative incidence of grade 3 and 4 clinical and laboratory adverse events

    Common Toxicity Criteria for Adverse Events version 5.0

    Time frame: Days 1-28

  12. Cumulative incidence of serious adverse events

    Serious adverse events standard definition

    Time frame: Days 1-28

  13. Cumulative incidence of adverse events of special interest

    Adverse events of special interest for test article and bronchoalveolar lavage

    Time frame: Days 1-28

Other outcomes

  1. Ventilator-free Days

    Days alive and free of invasive mechanical ventilation

    Time frame: Days 1-28

  2. Mortality

    All-cause mortality

    Time frame: Day 1-28

07

Study locations

2 of 2 sites recruiting
  • Harborview Medical Center
    Seattle, Washington 98104, United States
    Recruiting
    • Linzee Mabrey, MD · Contact
    • Linzee Mabrey, MD · Principal investigator
  • University of Washington
    Seattle, Washington 98195, United States
    Recruiting
    • Linzee Mabrey, MD, MSc · Contactmflinzee@uw.edu · (206) 731-4165
    • Eric Morrell, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2029, 32 months after the start.

Of 59 phase 2 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 32 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jul 22, 2024
StartActual
Jun 17, 2026
Primary completionEst.
Mar 1, 2029
CompletionEst.
Jun 1, 2029
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06513949
Lead sponsor
Implicit Bioscience
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Jun 17, 2026
Primary completion
Mar 1, 2029 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Jul 29, 2026

Study contacts

Linzee Mabrey, MD, MSc
Contact
mflinzee@uw.edu
(206) 897-5051
Linzee Mabrey, MD, MsC
principal investigator · Unversity of Washington

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atibuclimab

Start the discussion